<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586920</url>
  </required_header>
  <id_info>
    <org_study_id>17797</org_study_id>
    <secondary_id>J3D-MC-FNAA</secondary_id>
    <secondary_id>2020-003957-30</secondary_id>
    <nct_id>NCT04586920</nct_id>
  </id_info>
  <brief_title>A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants</brief_title>
  <official_title>A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of&#xD;
      LY3509754 and any side effects that might be associated with it. Blood tests will be&#xD;
      performed to check how much LY3509754 gets into the bloodstream and how long it takes the&#xD;
      body to eliminate it.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 26</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3509754</measure>
    <time_frame>Predose up to 96 hours postdose</time_frame>
    <description>PK: Cmax of LY3509754</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3509754</measure>
    <time_frame>Predose up to 96 hours postdose</time_frame>
    <description>PK: AUC of LY3509754</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3509754 - Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of LY3509754 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3509754 plus Itraconazole - Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3509754 and Itraconazole administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Itraconazole - Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Itraconazole administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3509754 plus Midazolam - Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Midazolam - Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3509754 (Japanese) - Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3509754 administered orally to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Japanese) - Part D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally to Japanese participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3509754</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3509754 (Japanese) - Part D</arm_group_label>
    <arm_group_label>LY3509754 - Part A</arm_group_label>
    <arm_group_label>LY3509754 plus Itraconazole - Part B</arm_group_label>
    <arm_group_label>LY3509754 plus Midazolam - Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo (Japanese) - Part D</arm_group_label>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_label>Placebo plus Itraconazole - Part B</arm_group_label>
    <arm_group_label>Placebo plus Midazolam - Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3509754 plus Itraconazole - Part B</arm_group_label>
    <arm_group_label>Placebo plus Itraconazole - Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3509754 plus Midazolam - Part C</arm_group_label>
    <arm_group_label>Placebo plus Midazolam - Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males or females, as determined by medical history and physical&#xD;
             examination.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18 to 35 kilograms per meter squared (kg/m²)&#xD;
             in Parts A, B, and C. In Part D (Japanese participants), body weight between 50 and 85&#xD;
             kg and BMI within the range of 18 to 28 kg/m².&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating LY3509754, and have previously received LY3509754.&#xD;
&#xD;
          -  Women of childbearing potential are excluded from the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

